Niagen Bioscience, Inc Stock Price, News & Analysis

Niagen Bioscience (NASDAQ: NAGE), a company focused on NAD+ and healthy aging science, announced its participation in Canaccord Genuity's 45th Annual Growth Conference from August 12-14, 2024, in Boston.

CEO Rob Fried and CFO Ozan Pamir will participate in a fireside chat on August 12 at 12:00 PM ET. The executives will also conduct one-on-one meetings with institutional investors during the conference. The presentation will be available via webcast, with a replay accessible on the company's investor relations website.

Niagen Bioscience (NASDAQ: NAGE), a company focused on NAD+ and healthy aging science, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025.

The company will release its Q2 2025 financial results after market close, followed by an investor conference call at 4:30 p.m. ET. Management will discuss the financial performance and provide a business update during the call, which will be accessible via webcast through the company's investor relations website.

Niagen Bioscience (NASDAQ: NAGE) has announced the debut of its flagship products at Equinox Hotel New York. Tru Niagen®, the leading NAD+ supplement in the US, will be available as an in-room amenity, while Niagen IV will be offered at the hotel's spa through NutriDrip.

The partnership aims to provide hotel guests with science-backed cellular health benefits through Niagen® (patented nicotinamide riboside), which supports cellular energy production and DNA repair. The collaboration with Equinox Hotel and NutriDrip represents Niagen Bioscience's strategy to expand consumer access and capture new market opportunities.

Niagen Bioscience (NASDAQ: NAGE) has secured a worldwide exclusive commercial license agreement with Haukeland University Hospital in Bergen, Norway, to develop and commercialize its NAD+ precursor Niagen® (nicotinamide riboside) as a potential Parkinson's Disease therapy.

The agreement grants exclusive rights to proprietary intellectual property and data, including results from the NOPARK trial - a phase III clinical study involving 400 early-stage Parkinson's patients across 12 Norwegian sites. The 52-week study, completed in June 2025, evaluated 500mg of Niagen twice daily versus placebo.

This collaboration builds on previous research partnerships dating back to March 2018, which have resulted in over 300 research collaborations and more than 35 peer-reviewed clinical studies. The company has established a new subsidiary to transition from supplement science to regulated drug development.

Niagen Bioscience (NASDAQ: NAGE), a company focused on NAD+ science and healthy aging, announced its participation in the upcoming Roth 15th Annual London Conference. The event will take place at the Four Seasons Hotel London at Park Lane from June 24-26, 2025. CFO Ozan Pamir will represent the company and conduct one-on-one meetings with institutional investors throughout the conference. The company, formerly known as ChromaDex Corp., continues to position itself as a global authority in NAD+ research and healthy aging solutions.

Niagen Bioscience (NASDAQ: NAGE), formerly ChromaDex Corp., has announced its participation in the 2025 BIO International Convention from June 16-19 in Boston. The event, hosted by the Biotechnology Innovation Organization, is the world's largest biotechnology convention, attracting over 20,000 global leaders from biopharma, academia, investment, and government sectors. The company aims to engage in discussions with potential partners to advance its drug product candidates, particularly focusing on neurodegenerative diseases like Parkinson's and Ataxia Telangiectasia. Key executives attending include CFO Ozan Pamir, SVP Andrew Shao, and Senior Global Director Yasmeen Nkrumah-Elie.

Niagen Bioscience (NASDAQ: NAGE) has announced groundbreaking results from the first-ever peer-reviewed study of nicotinamide riboside (NR) in Werner Syndrome (WS), a rare genetic aging disorder. The 52-week double-blind, placebo-controlled study showed that daily 1,000mg Niagen supplementation increased blood NAD+ levels by 140% and improved cardiovascular and skin health markers in WS patients. The study, published in Aging Cell, demonstrated significant improvements in arterial stiffness, HDL particle size, and wound healing. This research expands Niagen's rare disease portfolio, which includes promising results in Ataxia Telangiectasia (AT), where the company has received FDA Orphan Drug and Rare Pediatric Disease Designations. The study involved nine participants with WS and reported no moderate or severe adverse events, establishing a positive safety profile for NR supplementation in this population.

Niagen Bioscience (NASDAQ: NAGE), a company focused on NAD+ and healthy aging science, announced its participation in Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference. CEO Rob Fried will engage in a fireside chat on June 9, 2025, from 2:15 PM to 2:50 PM ET. Both CEO Rob Fried and CFO Ozan Pamir will conduct one-on-one meetings with institutional investors during the event. The fireside chat will be available via webcast, with a replay accessible on the company's investor relations website. The company, formerly known as ChromaDex Corp., specializes in nicotinamide adenine dinucleotide (NAD+) research and its applications in healthy aging.

Niagen Bioscience (NASDAQ:NAGE) reported strong Q1 2025 financial results with total net sales of $30.5 million, up 38% year-over-year. The company's flagship product Tru Niagen® generated $21.5 million in sales (up 24% YoY), while Niagen® ingredient sales reached $8.0 million (up 95% YoY). Key financial metrics include a gross margin of 63.4% (up 270 basis points), net income of $5.1 million ($0.07 EPS), and Adjusted EBITDA of $4.9 million. The company increased its 2025 outlook, projecting net sales growth of 20-25% (up from 18%). Recently, Niagen rebranded from its previous name and expanded its NAD+ precursor patent portfolio with a new patent covering nicotinamide riboside salt forms.